Clarity Pharmaceuticals Ltd
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceuticals products for oncology in Australia and the United States. The company's lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic ra… Read more
Clarity Pharmaceuticals Ltd (CLRPF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2023: -0.079x
Based on the latest financial reports, Clarity Pharmaceuticals Ltd (CLRPF) has a cash flow conversion efficiency ratio of -0.079x as of June 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.48 Million) by net assets ($69.18 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Clarity Pharmaceuticals Ltd - Cash Flow Conversion Efficiency Trend (2022–2023)
This chart illustrates how Clarity Pharmaceuticals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Clarity Pharmaceuticals Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Clarity Pharmaceuticals Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bold Eagle Acquisition Corp. Class A Ordinary Shares
NASDAQ:BEAG
|
-0.001x |
|
CHINA YOUZAN LTD. HD-01
F:YSZ
|
N/A |
|
Malteries Franco-Belges Société Anonyme
PA:MALT
|
0.020x |
|
Dirui Industrial Co Ltd
SHE:300396
|
-0.026x |
|
Anhui Wanyi Science and Technology Co Ltd
SHG:688600
|
0.069x |
|
ProFrac Holding Corp.
NASDAQ:ACDC
|
0.001x |
|
Samyang Holdings Corp
KO:000075
|
0.036x |
|
Prenetics Global Ltd
NASDAQ:PRE
|
0.023x |
Annual Cash Flow Conversion Efficiency for Clarity Pharmaceuticals Ltd (2022–2023)
The table below shows the annual cash flow conversion efficiency of Clarity Pharmaceuticals Ltd from 2022 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-06-30 | $69.18 Million | $-27.50 Million | -0.398x | -175.41% |
| 2022-06-30 | $92.24 Million | $-13.31 Million | -0.144x | -- |